Dupixent gains chronic spontaneous urticaria indication in Europe
Regeneron and Sanofi’s Dupixent (dupilumab) has gained approval to treat chronic spontaneous urticaria (CSU) in Europe, adding yet another indication to…
Dermatology
-
-
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer
Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in the US from Biofrontera…
-
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata.…
-
Galderma outlays $650m for US manufacturing as Nemluvio sales soar
Galderma has pledged to invest more than $650m on US manufacturing, as the drugmaker looks to meet increasing demand for…
-
Astria Therapeutics licenses navenibart rights to Kaken for HAE
Astria Therapeutics has entered an exclusive licensing agreement with Kaken Pharmaceutical for the development and commercialisation rights of navenibart in…
-
J&J seeks FDA approval for icotrokinra to treat psoriasis
Johnson & Johnson (J&J) has submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration…
-
LEO Pharma secures rights to Boehringer’s Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening…
-
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults…
-
‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the…
-
Ascletis’s daily acne tablet set for China review after Phase III win
Sagimet Bioscience’s denifanstat, a one-daily pill for the treatment of acne, has succeeded in a Phase III trial, with the…
